Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bristol-Myers Squibb (NY:BMY)

48.26 -0.08 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
From Bristol Myers Squibb
Via Business Wire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
From Bristol Myers Squibb
Via Business Wire
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
From Bristol Myers Squibb
Via Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus
From Philogen S.p.A.
Via GlobeNewswire
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.